Recombinant proteins with CD40 activating properties
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paris Est Creteil Val De Marne, Baylor Research Institute, Assistance Publique-HôPitaux De Paris (Aphp)
InventorsYves Levy, Valentina Ceglia, Sandra Zurawski, Gerard Zurawski
Life of this patent
Estimating the term…
Abstract
CD40 activating proteins comprising recombinant proteins with CD40 agonist antibodies or their antigen-binding fragments fused or linked to CD40 ligand are provided. The CD40 activating proteins may further comprise at least one antigen. Uses for the CD40 activating proteins include inducing immune responses directed to delivered antigens such as viral or cancer antigens. Properties of the CD40 activating protein may include the ability to induce proliferation of B cells or secretion of cytokines, such as IL-6, IL-12 and/or IL-15.
Claims17
A CD40 activating protein comprising at least the following protein domains:
- i) a CD40 agonist antibody or an antigen-binding fragment thereof (αCD40);
- and, ii) a CD40 binding-domain of CD40L wherein the CD40 agonist antibody is selected from:
- a) a humanized antibody comprising an HCDR1 of SEQ ID NO:
- 27, HCDR2 of SEQ ID NO:
- 28, HCDR3 of SEQ ID NO:
- 29, LCDR1 of SEQ ID NO:
- 30, LCDR2 of SEQ ID NO:
- 31 and LCDR3 of SEQ ID NO:
- 32;
- b) a humanized antibody comprising an HCDR1 of SEQ ID NO:
- 74, HCDR2 of SEQ ID NO:
- 75, HCDR3 of SEQ ID NO:
- 76, LCDR1 of SEQ ID NO:
- 77, LCDR2 of SEQ ID NO:
- 78 and LCDR3 of SEQ ID NO:
- 79;
- c) a humanized antibody comprising an HCDR1 of SEQ ID NO:
- 80, HCDR2 of SEQ ID NO:
- 81, HCDR3 of SEQ ID NO:
- 82, LCDR1 of SEQ ID NO:
- 83, LCDR2 of SEQ ID NO:
- 84 and LCDR3 of SEQ ID NO:
- 85;
- d) a humanized antibody comprising an HCDR1 of SEQ ID NO:
- 86, HCDR2 of SEQ ID NO:
- 87, HCDR3 of SEQ ID NO:
- 88, LCDR1 of SEQ ID NO:
- 89, LCDR2 of SEQ ID NO:
- 90 and LCDR3 of SEQ ID NO:
- 91;
- e) a humanized antibody comprising VH and VL domains of SEQ ID NO:
- 21 and SEQ ID NO:
- 22, respectively;
- f) a humanized antibody comprising VH and VL domains of SEQ ID NO:
- 23 and SEQ ID NO:
- 22, respectively;
- g) a humanized antibody comprising VH and VL domains of SEQ ID NO:
- 58 and SEQ ID NO:
- 59, respectively;
- h) a humanized antibody comprising VH and VL domains of SEQ ID NO:
- 60 and SEQ ID NO:
- 61, respectively;
- and i) a humanized antibody comprising VH and VL domains of SEQ ID NO:
- 62 and SEQ ID NO:
- 63, respectively;
- wherein the binding domain of CD40L is a fragment of CD40L comprising SEQ ID NO:14;
- and wherein the binding domain of CD40L is fused to the C-terminus of a light or a heavy chain of said CD40 agonist antibody or an antigen binding fragment thereof, optionally via a peptide linker.
Dependencies are inferred from the claim text.